Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report

Bastos, André Luis Carvalho de Moura; Freitas, Bruno de Paula; Boas, Oscar Villas; Ramiro, Alexandre Campelo

doi:10.1590/s0004-27492008000200030

Cited by 15 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior reports showed that the use of a topical carbonic anhydrase inhibitor (CAI) is effective for the improvement of CME with a modest increase in the visual acuity (in some of the subjects) in patients with retinal dystrophies such as retinitis pigmentosa, 11,12 X-linked retinoschisis, 7,13 and enhanced S-cone syndrome. 9,14 …”

Section: Introductionmentioning

confidence: 99%

Topical Dorzolamide for Treatment of Cystoid Macular Edema in Patients With Choroideremia

Genead

McAnany

Fishman

2012

Retina

View full text Add to dashboard Cite

Purpose To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema (CME). Methods Two choroideremia patients with CME, observed by spectral-domain optical coherence tomography (SD-OCT), were treated with a topical form of carbonic anhydrase inhibitor. Examinations performed before and during treatment included: best corrected visual acuity (BCVA) by using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, contrast sensitivity measured with briefly presented grating targets (grating CS) and the Pelli-Robson chart (P-R CS), microperimetry (MP), and SD-OCT. Results The two choroideremia patients treated with dorzolamide 2% formulation had a noticeable reduction in macular thickness by SD-OCT. This reduction was found in both eyes after 2 months of treatment. After an additional 3 months of the same treatment regimen, a more noticeable reduction in macular thickness was observed. The two study patients had improvement of their visual acuity, in at least one eye, on ETDRS charts, but no clinically significant changes for the other measures of visual function. Conclusion The present study shows the potential efficacy of topical dorzolamide for treating choroideremia patients with CME.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical Dorzolamide for Treatment of Cystoid Macular Edema in Patients With Choroideremia

Genead

McAnany

Fishman

2012

Retina

View full text Add to dashboard Cite

show abstract

“…(5) Literature considers the possibility of stabilization of VA around 20/70 during the second decade of life, with possible progression to atrophic maculopathy around 60 years old. (5,9) The treatment aims to prevent complications that increase visual loss, since nothing has been proven effective in preventing the development of the disease. (2) The possibility of treatment with topical dorzolamide is being studied, but still remains unproven.…”

Section: Discussionmentioning

confidence: 99%

“…(2) The possibility of treatment with topical dorzolamide is being studied, but still remains unproven. (6,9,10) In cases of vitreous hemorrhage, some authors suggest the use of photocoagulation of the vessels responsible for the bleeding. (11,12) But in cases of retinal detachment, a tamponade on the rupture and vitrectomy via pars plana are indicated.…”

Section: Discussionmentioning

confidence: 99%

X-linked juvenile retinoschisis

Silveira¹,

Soares²,

Provenzano³

2015

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

The authors declare no conflicts of interest RESUMORelatar o caso de um paciente masculino de 28 anos, que foi encaminhado ao Centro de Estudos e Pesquisas Oculistas Associados -RJ, para avaliação de retina e apresentou os achados típicos de Retinosquise Juvenil Ligada ao Cromossomo X: maculopatia cistóide com formação de cistos na fóvea e retinosquise periférica. Foi realizado o manejo conservador, com atenção para as complicações.Descritores: Retinosquise/diagnóstico; Doenças genéticas ligadas ao cromossomo X/diagnóstico; Relatos de casos ABSTRACT

show abstract

“…Recentemente, alguns estudos estão tentando determinar a importância da dorzolamida tópica no tratamento das lesões foveais da retinosquise juvenil ligada ao X (3,15) .…”

Section: Discussionunclassified

“…Trata-se de uma doença de caráter recessivo ligado ao X, sendo a causa mais comum de degeneração macular juvenil em homens (1,2) . Estima-se sua prevalência em 1:5000 a 1:25000 (3) .…”

Section: Introductionunclassified

Uso da dorzolamida tópica em paciente portador de retinosquise juvenil ligada ao X

Caye¹,

Barbosa

Scheid³

et al. 2010

Rev. bras.oftalmol.

View full text Add to dashboard Cite

RESUMOA retinosquise juvenil ligada ao cromossomo X é uma degeneração vítreorretiniana hereditária e recessiva. Sua manifestação ocular é a maculopatia cística bilateral e a delaminação das camadas de fibras nervosas da retina. Nenhuma intervenção terapêu-tica se mostrou eficiente para estabilizar a acuidade visual nestes pacientes. O artigo relata o caso clínico de um paciente portador de retinosquise juvenil ligada ao cromossomo X, que foi tratado com o uso tópico da dorzolamida, um colírio inibidor da anidrase carbônica.

show abstract

Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report

Cited by 15 publications

References 19 publications

Topical Dorzolamide for Treatment of Cystoid Macular Edema in Patients With Choroideremia

Topical Dorzolamide for Treatment of Cystoid Macular Edema in Patients With Choroideremia

X-linked juvenile retinoschisis

Uso da dorzolamida tópica em paciente portador de retinosquise juvenil ligada ao X

Contact Info

Product

Resources

About